Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
Ajinkya M PawarRishi J DesaiDaniel H SolomonAdrian J Santiago OrtizSara GaleMin BaoKhaled SarsourSebastian SchneeweissSeoyoung C KimPublished in: Annals of the rheumatic diseases (2019)
This large multidatabase cohort study found no difference in composite SI risk in patients with RA initiating TCZ versus TNFi after failing ≥1 biologic drug or tofacitinib. However, the risk of serious bacterial infection, skin and soft tissue infections, and diverticulitis was higher in TCZ versus TNFi initiators. The risk of composite SI was higher in TCZ initiators versus abatacept.